- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07144436
- Original Trial
Post-stroke Pain tAN-fMRI
Investigating the Feasibility, Efficacy, and Renormalization of Pain-Regulation Brain Circuits Underlying At-Home Transcutaneous Auricular Neuromodulation (tAN) for Managing Chronic Post-Stroke Pain
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In this study, the investigators main goal is to establish transcutaneous auricular neurostimulation (tAN) as an effective non-invasive neuromodulation method for pain management of post-stroke pain (PSP) and to investigate the brain circuit changes between pre- and post-treatment in individuals with PSP using brain imaging techniques.
Aim 1. Assess the feasibility and efficacy of self-administered, at-home tAN for pain management in stroke survivors with chronic pain compared to sham.
Aim 2. Investigate pain-induced brain activity changes over a one-month tAN treatment to understand the analgesic mechanisms of tAN.
Aim 3. Explore renormalization of brain functional connectivity and dynamic brain state throughout tAN treatment and develop brain imaging biomarkers to track and predict treatment efficacy for chronic post-stroke pain.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Institutional RBFHR Recruitment Contact
- Phone Number: 843-792-9502
- Email: suttonf@musc.edu
Study Locations
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Recruiting
- 30 Bee Street
-
Contact:
- Falon Sutton
- Phone Number: 8437929502
- Email: suttonf@musc.edu
-
Charleston, South Carolina, United States, 29425
- Not yet recruiting
- Medical University of South Carolia
-
Contact:
- Falon Sutton
- Phone Number: 843-792-9502
- Email: suttonf@musc.edu
-
Principal Investigator:
- Xiaolong Peng, Ph.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18-80
- Have the capacity and ability to provide one's own consent in English and sign the informed consent document.
- Ischemic or hemorrhagic stroke that occurred at least 6 months prior
Exclusion Criteria:
- Primary intracerebral hematoma or subarachnoid hemorrhage
- Documented history of dementia
- Documented history of uncontrolled depression or psychiatric disorder
- Uncontrolled hypertension despite treatment, specifically SBP (Systolic Blood Pressure) / DBP (Diastolic Blood Pressure) >=180/100mmHg
- Contraindicated for MRI scanning
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: 2 Weeks Sham tAN followed by 2 Weeks Active tAN
Participants will be randomized to receive 2 weeks of at-home, self-administered sham Transcutaneous Auricular Neurostimulation (tAN), followed by 2 weeks of at-home, self-administered active Transcutaneous Auricular Neurostimulation (tAN).
|
Transcutaneous Auricular Neurostimulation (tAN) is a wearable, electrical stimulation device that delivers electricity to specific parts of the human ear.
|
|
Experimental: Four Weeks of Active Transcutaneous Auricular Neurostimulation
Participants will be randomized to receive 2 weeks of at-home, self-administered active Transcutaneous Auricular Neurostimulation (tAN), followed by 2 additional weeks of at-home, self-administered active Transcutaneous Auricular Neurostimulation (tAN).
|
Transcutaneous Auricular Neurostimulation (tAN) is a wearable, electrical stimulation device that delivers electricity to specific parts of the human ear.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sensory Threshold
Time Frame: 4 weeks
|
We will determine the pain threshold with a 30 × 30 mm thermode attached to the non-affected forearm of participants (TSA2 thermode; Medoc, Durham, NC, USA).
Using the TSA2, we will determine heat sensitivity beginning at 32°C and increasing by 0.5°C per second.
Participants will be asked to press a button (to record temperatures) when the stimulus is first detected (sensory threshold).
We will acquire QST data at baseline, after one session (30 minutes) of tAN, after 2 weeks of tAN, and after 4 weeks of tAN.
|
4 weeks
|
|
Pain Threshold
Time Frame: 4 weeks
|
We will determine the pain threshold with a 30 × 30 mm thermode attached to the non-affected forearm of participants (TSA2 thermode; Medoc, Durham, NC, USA).
Using the TSA2, we will determine heat sensitivity beginning at 32°C and increasing by 0.5°C per second.
Participants will be asked to press a button (to record temperatures) when the stimulus becomes painful (pain threshold).
We will acquire QST data at baseline, after one session (30 minutes) of tAN, after 2 weeks of tAN, and after 4 weeks of tAN.
|
4 weeks
|
|
Pain tolerance
Time Frame: 4 weeks
|
We will determine the pain threshold with a 30 × 30 mm thermode attached to the non-affected forearm of participants (TSA2 thermode; Medoc, Durham, NC, USA).
Using the TSA2, we will determine heat sensitivity beginning at 32°C and increasing by 0.5°C per second.
Participants will be asked to press a button (to record temperatures) when the stimulus is intolerable (pain tolerance).
We will acquire QST data at baseline, after one session (30 minutes) of tAN, after 2 weeks of tAN, and after 4 weeks of tAN.
|
4 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Xiaolong Peng, Ph.D., Medical University of South Carolina
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00145968
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.